Your browser is no longer supported. Please, upgrade your browser.
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own0.90% Shs Outstand172.48M Perf Week0.22%
Market Cap20.41B Forward P/E- EPS next Y-1.28 Insider Trans-19.04% Shs Float170.93M Perf Month8.89%
Income-158.70M PEG- EPS next Q-0.74 Inst Own94.30% Short Float2.90% Perf Quarter2.25%
Sales916.70M P/S22.26 EPS this Y32.10% Inst Trans-3.51% Short Ratio4.54 Perf Half Y50.49%
Book/sh10.93 P/B10.83 EPS next Y51.70% ROA-8.50% Target Price125.75 Perf Year69.62%
Cash/sh4.70 P/C25.16 EPS next 5Y23.00% ROE-10.20% 52W Range62.90 - 124.32 Perf YTD3.56%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-6.02% Beta1.95
Dividend %- Quick Ratio4.20 Sales past 5Y26.20% Gross Margin95.20% 52W Low85.76% ATR3.92
Employees1605 Current Ratio4.50 Sales Q/Q66.10% Oper. Margin-24.10% RSI (14)52.74 Volatility2.51% 3.52%
OptionableYes Debt/Eq0.00 EPS Q/Q120.10% Profit Margin-17.30% Rel Volume0.76 Prev Close118.33
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume1.09M Price116.84
Recom2.20 SMA201.43% SMA503.07% SMA20030.45% Volume573,319 Change-1.26%
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Feb-19-20 05:12PM  Seattle Genetics bladder drug gets breakthrough therapy designation American City Business Journals
09:21AM  Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates Zacks
08:28AM  Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer PR Newswire
08:12AM  Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer Business Wire
Feb-13-20 08:00AM  Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 08:00AM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer Business Wire
Feb-10-20 07:01PM  Edited Transcript of SGEN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
05:00PM  Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer PR Newswire
10:51AM  Seattle Genetics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
09:37AM  3 Nasdaq 100 Stocks With Excellent Upside Potential Investopedia
Feb-07-20 11:15AM  Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales Zacks
Feb-06-20 05:25PM  Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:07PM  Biotech Giant Crushes Sales Estimates And Posts A Profit But Shares Dive Investor's Business Daily
04:02PM  Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
02:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 09:45AM  Why Seattle Genetics (SGEN) Might Surprise This Earnings Season Zacks +6.09%
Jan-31-20 08:00AM  EMA Validates Seattle Genetics Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Jan-30-20 12:31PM  Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jan-21-20 06:13PM  Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe Zacks
08:30AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020 Business Wire
08:00AM  Seattle Genetics Achieves Milestone Following European Commission Approval of Roches Polivy® (Polatuzumab Vedotin) Business Wire
Jan-20-20 09:32AM  Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-16-20 08:56AM  How Much is Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Getting Paid? Simply Wall St.
Jan-09-20 04:24PM  How Did Seattle Genetics, Inc. (SGEN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-30-19 10:09AM  Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline Zacks
Dec-26-19 08:13PM  What could you have made by investing $1,000 in these Washington companies a decade ago? American City Business Journals
02:47PM  Tech will drive change in health care throughout next decade American City Business Journals
Dec-24-19 01:12PM  Seattle Genetics Submits NDA to FDA for Tucatinib Combo Zacks
Dec-23-19 08:00AM  Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-19-19 03:17PM  Seattle Genetics gets accelerated approval for cancer-killing drug American City Business Journals
12:02PM  Seattle Genetics' stock rises on approval of bladder cancer drug MarketWatch
11:35AM  Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug Zacks
10:37AM  Why This Leading Biotech Stock Just Added To Its 99% Gain This Year Investor's Business Daily
09:07AM  Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod Benzinga
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 07:49PM  FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer PR Newswire
06:42PM  Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval Business Wire
06:36PM  FDA Grants Accelerated Approval to Astellas and Seattle Genetics PADCEV (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer Business Wire
08:00AM  Seattle Genetics Announces U.S. FDA Grants Breakthrough Therapy Designation for Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-12-19 04:57PM  Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal GuruFocus.com
Dec-11-19 10:31AM  When Will Seattle Genetics, Inc. (NASDAQ:SGEN) Turn A Profit? Simply Wall St.
09:54AM  Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine Business Wire
Dec-09-19 10:00AM  Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting Business Wire
Dec-07-19 02:00PM  Seattle Genetics Announces Updated Data of ADCETRIS® (Brentuximab Vedotin) in Combination with OPDIVO® (Nivolumab) in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting Business Wire
08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 11:49AM  Hedge Funds Had Impeccable Timing Buying Seattle Genetics, Inc. (SGEN) Insider Monkey
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
Dec-02-19 09:21PM  This is what workers earn at some of Washington's largest public companies American City Business Journals
08:00AM  Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer Business Wire
Nov-28-19 09:31AM  Seattle Genetics (SGEN) Up 15.7% Since Last Earnings Report: Can It Continue? Zacks
Nov-26-19 08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 08:00AM  Seattle Genetics Announces Health Canada Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy in Frontline CD30-Expressing Peripheral T-Cell Lymphoma Business Wire
Nov-21-19 09:56AM  The Medicines Company Soars Amid Acquisition Whispers Investopedia
Nov-13-19 07:10AM  The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher Benzinga
Nov-12-19 05:15PM  Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership Business Wire
Nov-07-19 08:00AM  Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting Business Wire
Nov-05-19 08:00AM  Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
Nov-04-19 11:51PM  Seattle Genetics Responds to Daiichi Sankyos Complaint for Declaratory Judgment Business Wire
08:00AM  Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference Business Wire
Nov-01-19 10:03AM  Baker Brothers Make $1.4 Billion in Two Weeks on Biotech Bloomberg
07:36AM  Edited Transcript of SGEN earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
Oct-29-19 05:25PM  Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM  Seattle Genetics Reports Third Quarter 2019 Financial Results Business Wire
Oct-27-19 12:56PM  The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings Benzinga
Oct-23-19 09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
Oct-22-19 10:06AM  Seattle Genetics: Where's This Biotech Stock Headed From Here? TheStreet.com
Oct-21-19 04:15PM  This Biotech Stock Piggybacked On Roche's Blockbuster And Succeeded Investor's Business Daily +15.43%
03:20PM  Seattle Genetics Options Volume Skyrockets as Shares Soar Schaeffer's Investment Research
12:59PM  Dow Jones Lags, Boeing Bombarded Again; These Growth Stocks Are Emerging As New Leaders Investor's Business Daily
12:42PM  Baker Brothers Makes $730 Million in One Day on Its Biotech Bet Bloomberg
10:01AM  Here's Why We're Not At All Concerned With Seattle Genetics's (NASDAQ:SGEN) Cash Burn Situation Simply Wall St.
09:58AM  Seattle Genetics stock soars 15% on positive trial of breast cancer treatment MarketWatch
09:36AM  Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study Benzinga
07:04AM  Seattle Genetics Shares Rise On Positive Results From Breast Cancer Drug Trial TheStreet.com
06:45AM  Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-16-19 03:23PM  Four stocks that are nearing key breakouts MarketWatch
11:51AM  4 Stocks Nearing Key Breakouts Benzinga
Oct-12-19 02:16PM  Did Hedge Funds Drop The Ball On Seattle Genetics, Inc. (SGEN) ? Insider Monkey
Oct-11-19 12:40PM  Seattle Genetics Begins Phase III Study on Tucatinib Combo Zacks
Oct-10-19 11:15AM  Seattle Genetics Up More Than 20% in 3 Months: Here's Why Zacks
08:00AM  Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-08-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019 Business Wire
Oct-06-19 07:55AM  Goldman Sachs: 3 Stocks to Buy Despite Recession Fears TipRanks
Oct-01-19 04:42PM  Immunomedics (IMMU) Reports Interim Urothelial Cancer Data Zacks
12:58PM  A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019 Benzinga
11:45AM  Seattle Genetics Up on Positive Data From Bladder Cancer Study Zacks
09:42AM  Company News For Oct 1, 2019 Zacks
Sep-30-19 04:31PM  Why This Biotech Stock Just Broke Out In Bullish Volume And Another Toppled Investor's Business Daily +12.37%
02:07PM  Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference Barrons.com
01:13PM  Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More Benzinga
12:05PM  A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019 Benzinga
09:15AM  Seattle Genetics Climbs on Positive Trial Results for Bladder Cancer Treatment TheStreet.com
08:33AM  Immunomedics Stock Drops After Bladder-Cancer-Drug Results Disappoint TheStreet.com
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; Agensys, Inc.; and Merck. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.0028,472341,664770,104Oct 10 06:55 PM
SIEGALL CLAY BPresident and CEOOct 08Sale82.4728,4722,348,061755,684Oct 10 06:55 PM
GRYSKA DAVID WDirectorOct 01Option Exercise15.895,00079,45050,513Oct 03 07:38 PM
GRYSKA DAVID WDirectorOct 01Sale85.095,000425,45048,013Oct 03 07:38 PM
SIMPSON TODD EChief Financial OfficerSep 30Sale85.0015,0001,275,000157,567Oct 02 06:12 PM
LIU JEAN IGC/EVP, Leg AffairsSep 30Sale86.007,432639,15270,688Oct 02 06:10 PM
DANSEY ROGER DChief Medical OfficerSep 25Sale73.803,000221,415103,146Sep 27 06:12 PM
SIEGALL CLAY BPresident and CEOSep 09Option Exercise12.0028,472341,664774,374Sep 10 07:29 PM
SIEGALL CLAY BPresident and CEOSep 09Sale68.3328,4721,945,531755,684Sep 10 07:29 PM
HIMES VAUGHN BSee RemarksSep 03Sale70.805,692402,990187,518Sep 04 09:45 PM
SIEGALL CLAY BSee RemarksSep 03Sale70.809,693686,257755,684Sep 04 09:46 PM
DANSEY ROGER DSee RemarksSep 03Sale70.8092265,277106,146Sep 04 09:43 PM
SIMPSON TODD ESee RemarksSep 03Sale70.802,092148,112172,567Sep 04 09:42 PM
HIMES VAUGHN BSee RemarksAug 30Option Exercise12.008,00096,000201,210Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Sale72.868,000582,859193,210Sep 04 09:45 PM
LIU JEAN IGC/EVP, Leg AffairsAug 28Sale73.226,013440,24260,904Aug 30 04:35 PM
SIEGALL CLAY BPresident and CEOAug 28Sale73.2128,9512,119,636717,343Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale73.215,909432,624153,371Aug 30 04:36 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale73.216,836500,496175,197Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 20Sale80.0012,5001,000,000159,280Aug 22 05:49 PM
LIU JEAN IGC/EVP, Leg AffairsAug 20Sale80.003,716297,28066,917Aug 22 05:47 PM
SIEGALL CLAY BPresident and CEOAug 08Option Exercise12.1620,149245,012756,192Aug 09 05:06 PM
SIEGALL CLAY BPresident and CEOAug 08Sale76.5220,1491,541,827746,294Aug 09 05:06 PM
LIU JEAN IGC/EVP, Leg AffairsAug 06Sale75.003,716278,70070,633Aug 08 05:42 PM
GRYSKA DAVID WDirectorJul 17Option Exercise12.765,00063,80053,013Jul 19 06:20 PM
GRYSKA DAVID WDirectorJul 17Sale75.005,000375,00048,013Jul 19 06:20 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.1620,148245,000761,011Jul 10 06:57 PM
SIEGALL CLAY BPresident and CEOJul 08Sale66.8920,1481,347,664746,294Jul 10 06:57 PM
HIMES VAUGHN BChief Technical OfficerJun 24Option Exercise42.514,704199,970182,033Jun 26 06:26 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale68.605,416371,53877,593Jun 19 06:43 PM
SIEGALL CLAY BPresident and CEOJun 10Option Exercise12.1620,148245,000760,119Jun 12 05:51 PM
SIEGALL CLAY BPresident and CEOJun 10Sale69.0520,1481,391,175749,169Jun 12 05:51 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.008,00096,000185,329Jun 04 06:28 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale65.948,000527,485177,329Jun 04 06:28 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise12.164,82458,660752,063May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 09Sale67.434,824325,301749,169May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.1615,324186,340762,600May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Sale68.2615,3241,046,066749,169May 10 04:39 PM
BAKER BROS. ADVISORS LPDirectorApr 29Option Exercise8.3820,000167,60045,839,686May 01 04:59 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.1620,148245,000757,976Apr 10 04:39 PM
SIEGALL CLAY BPresident and CEOApr 08Sale79.2220,1481,596,100749,169Apr 10 04:39 PM
SIMPSON TODD EChief Financial OfficerApr 05Sale78.0012,500975,000171,780Apr 09 08:35 PM
GRYSKA DAVID WDirectorApr 01Option Exercise12.765,00063,80050,050Apr 03 08:57 PM
GRYSKA DAVID WDirectorApr 01Sale73.415,000367,03045,050Apr 03 08:57 PM
SIEGALL CLAY BPresident and CEOMar 18Option Exercise12.0816,556199,988749,169Mar 20 06:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Option Exercise12.008,00096,000185,329Mar 12 07:31 PM
SIEGALL CLAY BPresident and CEOMar 08Option Exercise12.1620,148245,000745,259Mar 12 07:34 PM
SIEGALL CLAY BPresident and CEOMar 08Sale69.1920,1481,394,094732,613Mar 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Sale68.728,000549,746177,329Mar 12 07:31 PM
SIMPSON TODD EChief Financial OfficerMar 04Sale75.0010,000750,000184,280Mar 06 06:58 PM